Abstract
Twenty percent of children with immune thrombocytopenia (ITP) develop a chronic course where treatment strategy is less established. Cyclosporin A (CSA) has been shown to be effective in small series of children with chronic ITP and might reduce the need for chronic steroid therapy and/or splenectomy. We reviewed consecutive patients below 18 years old with persistent or chronic ITP treated with CSA in our unit between January 1998 and June 2015. Thirty patients (14 boys and 16 girls) were included. The median age at initial diagnosis of ITP was 5 years (range 0.5–16.2 years). CSA was started at a median of 13.9 months (range 3.4–124 months) after initial diagnosis and given for a median duration of 9.3 months (range 0.2–63.9 months). The median platelet count before commencement was 12 × 109/L (range 4–199 × 109/L). The median dose of CSA was 6 mg/kg/day (range 2.4–7.5 mg/kg/day). Complete response (CR) or response (R) was achieved in 17 patients (57 %), and 7 (23 %) had sustained response. Side effects (most commonly hirsutism) were tolerable and reversible. CSA appeared effective in about half of persistent or chronic ITP patients and safe as a second-line agent in managing these children.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Neunert C, Lim W, Crowther M et al (2011) The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 117:4190–4207
Terrell DR, Beebe LA, Vesely SK et al (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85:174–180
Kühne T, Buchanan GR, Zimmerman S et al (2003) A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143:605–608
Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393
Provan D, Stasi R, Newland AC et al (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115:168–186
Aronis S, Platokouki H, Avgeri M et al (2004) Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 93:638–642
Gesundheit B, Cividalli G, Freeman A et al (2001) Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children. Eur J Haematol 66:347–351
Schultz K, Strahlendorf C, Warrier I, Ravindranath Y (1995) Cyclosporin A therapy of immune-mediated thrombocytopenia in children
Jain S, Kapoor S, Singh A et al (2012) Good response to cyclosporin in a child with acquired thrombocytopenic purpura. Indian J Pediatr 79:1236–1237
Perrotta S, Amendola G, Locatelli F et al (2003) Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol 121:143–147
Cui ZG, Liu XG, Qin P et al (2013) Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia. Chin Med J (Engl) 126:4145–4148
Choudhary DR, Naithani R, Mahapatra M et al. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura. Haematologica 2008; 93: e61-62; discussion e63
Williams JA, Boxer LA (2003) Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol 25:232–235
Moskowitz IP, Gaynon PS, Shahidi NT, Cripe TP (1999) Low-dose cyclosporin A therapy in children with refractory immune thrombocytopenic purpura. J Pediatr Hematol Oncol 21:77–79
Schultz KR, Strahlendorf C, Warrier I, Ravindranath Y (1995) Cyclosporin A therapy of immune-mediated thrombocytopenia in children. Blood 85:1406–1408
Liang Y, Zhang L, Gao J et al (2012) Rituximab for children with immune thrombocytopenia: a systematic review. PLoS One 7:e36698
Pei S-N, Chen C-H, Lee C-M et al (2010) Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 89:255–262
Bussel JB, de Miguel PG, Despotovic JM et al (2015) Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol 2:e315–e325
Grainger JD, Locatelli F, Chotsampancharoen T et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. The Lancet 2015
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Liu, A.P.Y., Cheuk, D.K.L., Lee, A.H.Y. et al. Cyclosporin A for persistent or chronic immune thrombocytopenia in children. Ann Hematol 95, 1881–1886 (2016). https://doi.org/10.1007/s00277-016-2791-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-016-2791-y